Target intervention against multiple-risk markers to reduce cardiovascular disease in patients with type 2 diabetes

被引：18

作者：

Gæde, P ^{[1
]}

Pedersen, O ^{[1
]}

机构：

[1] Steno Diabet Ctr, DK-2820 Copenhagen, Denmark

来源：

ANNALS OF MEDICINE | 2004年 / 36卷 / 05期

关键词：

cardiovascular disease; combined modality therapy; complication; nephropathy; neuropathy; retinopathy; risk factor; type; 2; diabetes;

D O I：

10.1080/07853890410033612

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The risk of cardiovascular disease is markedly increased in patients with type 2 diabetes with a prevalence twice as high compared to the background population. With the recognition of multiple concomitant risk factors for both microvascular as well as cardiovascular disease in type 2 diabetic patients, treatment strategies have changed during recent years. This review focuses on the many recent drug trials that have set the course for an effective multifactorial treatment of the disease. Thus, the Steno-2 Study has shown that an intensified multifactorial intervention targeting several risk factors for cardiovascular disease is capable of reducing the risk for a combined endpoint of cardiovascular mortality; non-fatal myocardial infarction, non-fatal stroke, coronary interventions, revascularisation to legs, and amputations by 50%.

引用

收藏

页码：355 / 366

页数：12

相关论文

共 48 条

[21] Randomised trial of old and new antihypertensive drugs in elderly patients:: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study [J].

Hansson, L ;

Lindholm, LH ;

Ekbom, T ;

Dahlöf, B ;

Lanke, J ;

Scherstén, B ;

Wester, PO ;

Hedner, T ;

de Faire, U .

LANCET, 1999, 354 (9192) :1751-1756

[22] Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].

Hansson, L ;

Zanchetti, A ;

Carruthers, SG ;

Dahlöf, B ;

Elmfeldt, D ;

Julius, S ;

Ménard, J ;

Rahn, KH ;

Wedel, H ;

Westerling, S .

LANCET, 1998, 351 (9118) :1755-1762

[23] FINAL REPORT ON THE ASPIRIN COMPONENT OF THE ONGOING PHYSICIANS HEALTH STUDY [J].

HENNEKENS, CH .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (03) :129-135

[24] TREATMENT ADHERENCE AND RISK OF DEATH AFTER A MYOCARDIAL-INFARCTION [J].

HORWITZ, RI ;

VISCOLI, CM ;

BERKMAN, L ;

DONALDSON, RM ;

HORWITZ, SM ;

MURRAY, CJ ;

RANSOHOFF, DF ;

SINDELAR, J .

LANCET, 1990, 336 (8714) :542-545

[25]

KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465

[26] n-3 polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study [J].

Lemaitre, RN ;

King, IB ;

Mozaffarian, D ;

Kuller, LH ;

Tracy, RP ;

Siscovick, DS .

AMERICAN JOURNAL OF CLINICAL NUTRITION, 2003, 77 (02) :319-325

[27] Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].

Lewis, EJ ;

Hunsicker, LG ;

Clarke, WR ;

Berl, T ;

Pohl, MA ;

Lewis, JB ;

Ritz, E ;

Atkins, RC ;

Rohde, R ;

Raz, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860

[28] THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON DIABETIC NEPHROPATHY [J].

LEWIS, EJ ;

HUNSICKER, LG ;

BAIN, RP ;

ROHDE, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (20) :1456-1462

[29] Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Lindholm, LH ;

Ibsen, H ;

Dahlöf, B ;

Devereux, RB ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Julius, S ;

Kjeldsen, SE ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H ;

Aurup, P ;

Edelman, J ;

Snapinn, S .

LANCET, 2002, 359 (9311) :1004-1010

[30]

LOGAN AG, 1979, LANCET, V2, P1175

← 1 2 3 4 5 →